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Estudo comparativo experimental da proteção miocárdica com soluções cristalóides para transplante
cardíaco
Comparative experimental study of myocardial
protection with crystalloid solutions for heart
transplantation
Abstract
Background: There is a growing need to improve
myocardial protection, which will lead to better performance
of cardiac operations and reduce morbidity and mortality.
Therefore, the objective of this study was to compare the
efficacy of myocardial protection solution using both
intracellular and extracellular crystalloid type regarding
the performance of the electrical conduction system, left
ventricular contractility and edema, after being subjected
to ischemic arrest and reperfusion.
Methods: Hearts isolated from male Wistar (n=32) rats
were prepared using Langendorff method and randomly
divided equally into four groups according the
cardioprotective solutions used Krebs-Henseleit-Buffer
(KHB), Bretschneider-HTK (HTK), St. Thomas-1 (STH-1)
and Celsior (CEL). After stabilization with KHB at 37°C,
baseline values (control) were collected for heart rate (HR),
left ventricle systolic pressure (LVSP), maximum first
derivate of rise left ventricular pressure (+dP/dt), maximum
first derivate of fall left ventricular pressure (-dP/dt) and
coronary flow (CF). The hearts were then perfused at 10°C
for 5 min and kept for 2 h in static ischemia at 20°C in each
cardioprotective solution. Data evaluation was done using
analysis of variance in completely randomized One-Way
ANOVA and Tukey’s test for multiple comparisons. The level
of statistical significance chosen was P<0.05.
Results: HR was restored with all the solutions used.
The evaluation of left ventricular contractility (LVSP, +dP/
dt and -dP/dt) showed that treatment with CEL solution was
better compared to other solutions. When analyzing the CF,
the HTK solution showed better protection against edema.
Conclusion: Despite the cardioprotective crystalloid
solutions studied are not fully able to suppress the
deleterious effects of ischemia and reperfusion in the rat
heart, the CEL solution had significantly higher results
followed by HTK>KHB>STH-1.
Keywords: Heart arrest, induced. Myocardial reperfusion
injury. Cardioplegic solutions. Ventricular function, left.
Rats, Wistar.
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INTRODUCTION
Currently, most heart surgeries are performed with anoxic
arrest induced by using different cardioplegic solutions,
suggesting the lack of a gold standard for myocardial
protection [1]. Procedures with short period of ischemia,
preservation is simpler. However, procedures where long
ischemic periods are common, myocardial viability may be
compromised by the current methods of myocardial
preservation [2]. Thus, establishing satisfactory method
of preservation is critical to ensure success in procedures
with prolonged ischemic time, particularly in cardiac
transplantation, which can also lead to expanding the pool
of donors [2].
Due to the shortage of donated hearts, selection criteria
are under constant review in order to increase the number
of marginal donors [3,4]. Nevertheless, studies in the field
of myocardial protection have great relevance for the
advancement of heart transplantation [1]. Prolonged
myocardial ischemia is an independent risk factor for early
and late survival of the patient [4].
The crystalloid cardioplegic solutions were initially
idealized in order to depolarize the cell membrane. Thus,
their initial formulations were basically ionic. The progress
of research on myocardial protection showed the need for
additives in the solutions to expand their effectiveness.
The main actions of additives aimed at removal of free
radicals, providing nutrients, prevention of intracellular
acidosis and stabilization of cell membranes to minimize
swelling [5].
Studies on myocardial protection with additives in the
solutions associated with hypothermia, demonstrated
improved contractile function after long periods of ischemia
[6]. Hypothermia protects cellular energy metabolism acting
improving the resistance to ischemia in cardioplegic cardiac
arrest [7]. The increase in the ratio between supply and
energy demand during ischemia is generally attributed to
hypothermic protection. The hypothermia also combats
oxidative stress induced by ischemia and reperfusion [8].
There is still growing need to further investigate and
improve heart preservation methods, thus improving
performance of cardiac operations, reducing morbidity,
increasing the donor pool, and extending its indications
and benefits [4].
The objective of this study was to compare the efficacy
of myocardial protection solution using both intracellular
de acordo com as soluções cardioprotetoras utilizadas Krebs-
Henseleit-Buffer (KHB), Bretschneider-HTK (HTK), St.
Thomas-1(STH-1) e Celsior (CEL). Após a estabilização com
KHB a 37°C, valores basais (controle) foram coletados para
frequência cardíaca (FC), pressão sistólica do ventrículo
esquerdo (PSVE), derivada máxima de aumento da pressão
ventricular esquerda (+dP/dt), derivada máxima de queda da
pressão ventricular esquerda (-dP/dt) e fluxo coronariano (FCo).
Os corações foram então perfundidos a 10°C por 5 min e
mantidos por 2 h em isquemia estática a 20°C em cada solução
cardioprotetora. Avaliação dos dados foi por análise de variância
inteiramente casualizados em One-Way ANOVA e teste de
Tukey para comparações múltiplas. O nível de significância
estatística escolhido foi P<0,05.
Resultados: Houve recuperação da FC com todas as
soluções utilizadas. A avaliação da contratilidade ventricular
esquerda (PSVE, +dP/dt e -dP/dt) demonstrou que o
tratamento com a solução CEL foi melhor em comparação às
outras soluções. Ao analisar o CF, a solução HTK indicou
melhor proteção contra edema.
Conclusão:  Apesar das soluções cristaloides
cardioprotetoras estudadas não serem capazes de suprimir
os efeitos deletérios da isquemia e reperfusão no coração de
ratos, a solução CEL apresentou resultado superior seguido
por HTK>KHB>STH-1.
Descritores: Parada cardíaca induzida. Traumatismo por
reperfusão miocárdica. Soluções cardioplégicas. Função
ventricular esquerda. Ratos Wistar.
Resumo
Introdução: Existe crescente necessidade de aprimorar a
proteção miocárdica, para melhor desempenho das operações
cardíacas e diminuição da morbimortalidade. Portanto, o
objetivo deste estudo foi comparar a eficácia da proteção
miocárdica usando tanto solução cristaloide tipo intracelular
como extracelular quanto ao desempenho do sistema de
condução elétrica, contratilidade do ventrículo esquerdo e
edema, após parada isquêmica e posterior reperfusão.
Métodos: Corações isolados de ratos Wistar foram montados
em Langendorff e aleatoriamente divididos em quatro grupos.
Abbreviations, acronyms & symbols
ABTO Brazilian Association for Organ Transplant /
Associação Brasileira de Transplante de Órgãos
CEL Celsior solution
CF coronary flow
COBEA Brazilian College of Animal Experimentation /
Colégio Brasileiro de Experimentação Animal
+dP/dt peak positive of the first derivative of left
ventricular pressure
-dP/dt peak negative of the first derivative of left
ventricular pressure
HR heart rate
HTK Bretschneider-HTK solution
KHB Krebs-Henseleit-Buffer solution
LVSP left ventricle systolic pressure
STH-1 St. Thomas No. 1 solution
STH-2 St. Thomas No. 2 solution
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and extracellular crystalloid type regarding the performance
of the electrical conduction system, left ventricular
contractility and edema, after being subjected to ischemic
arrest and reperfusion.
METHODS
The Brazilian College of Animal Experimentation
(COBEA) and the Ethics Committee of the Fundação
Cardiovascular São Francisco de Assis, Belo Horizonte,
Minas Gerais, Brazil, approved all experiments. All
experiments used an isolated isovolumetrically contracting
rat heart. Male Wistar albino rats (n=32), 310 to 320 g,
were anesthetized by intraperitoneal injection of a mixture
of ketamine (50 mg/kg) and xilazine (10 mg/kg). After the
chest was opened, heparin (500 IU) was injected into the
left atrium. An aortic cannula filled with perfusate was
rapidly inserted into the aorta, and retrograde perfusion
was started with an oxygenated Krebs-Henseleit buffer at
37°C and maintained at a constant pressure of 100 mmHg
in a single-pass way by the Langendorff technique [9].
The pulmonary artery was incised to allow outflow of the
perfusate. A latex balloon was placed in the left ventricle
and connected to a pressure transducer line. The balloon
was inflated with water to create a diastolic pressure of 7
to 9 mmHg. The hearts were beating spontaneously at an
average rate of 300 beats/min. After 15 min of perfusion at
37°C with KHB solution for stabilization, we collected the
values considered baseline (control) for the following
parameters: heart rate (HR) to evaluate the electrical
conduction system; left ventricle systolic pressure (LVSP),
the maximum rate of rise in left ventricular (+dP/dt), the
maximum rate of fall in left ventricular (-dP/dt) pressures
to evaluate the ventricular contractility and coronary flow
(CF) to evaluate the edema.
The hearts were randomly divided equally into four
groups, as follows: Group 1 were treated with Krebs-
Henseleit (KHB) solution (Research Laboratory of
Fundação Cardiovascular São Francisco de Assis, Belo
Horizonte, MG, Brazil), Group 2 with Bretschneider-HTK
(HTK) solution (Dr. Franz Köhler Chemie GMBH - Germany),
Group 3 with St. Thomas No. 1 (STH-1) solution (Braile
Biomédica Industry, Sâo Paulo, SP, Brazil), and Group 4
with Celsior (CEL) solution (Genzyme Polyclonals S.A.S.,
France).
The hearts were then perfused with their respective
cardioprotective solutions for 5 min at 10°C and kept for 2
h in static ischemia at 20°C. Subsequently, the hearts were
reperfused with KHB at 37°C for 60 min and data were
collected every 5 min. Data evaluation was based on
analysis of variance in completely randomized One-Way
ANOVA and Tukey’s test for multiple comparisons. The
criterion for significance was P<0.05 for all comparisons.
RESULTS
To evaluate myocardial protection, we first compared
the effect of the solutions on HR. Figure 1 shows the trend
in HR of the solutions used in the experiment at 10°C,
compared with the control, represented by a ratio of 1.0
(basal HR). CEL and KHB solutions provided a more stable
HR throughout the length of the experiment. On the other
hand, use of HTK and STH-1 solutions initially resulted in
lower HR, which increased after 15 min and 30 min,
respectively, and stabilized at a similar HR compared to the
other solutions. These results indicated that all four
solutions were able to recover the HR.
Fig. 1 - Heart rate (HR), according to the solution. Reperfused
hearts were monitored for 60 min after treatment with the following
solutions: Krebs-Henseleit Buffer, Bretschneider-HTK, St. Thomas
No. 1, and Celsior. Baseline was calculated after stabilization and
prior to treatment
Left ventricular contractility was represented by the
corresponding hemodynamic variables LVSP, (+dP/dt), and
(-dP/dt) (Figures 2 to 4). These variables show similar trends
with the different solutions. CEL solution was more stable
and with higher rates compared to the other solutions. With
the HTK solution, rates increased constantly throughout
the 60 min period, and were higher compared to STH-1 and
KHB. KHB solution resulted in higher rates for all variables
compared to STH-1, but was still lower than HTK at LVSP
and (-dP/dt). Despite these differences, KHB reached
approximately the same rate of (+dP/dt) after 40 min,
compared to HTK. The contractile performance of STH-1
was lower than the other solutions. Here, the data show
that treatment with CEL is superior to the others solutions.
Because the occurrence of edema, which is a negative
factor in the recovery of the heart, the CF was considered
in the corresponding hemodynamics variables dynamics.
All treatments showed a downward trend (Figure 5).
However, treatment with HTK solution produced higher
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flow values compared to the others. Moreover, these
treatments indicated a decreasing order of efficiency:
HTK>CEL>KHB>STH-1. Together, these results indicate
that performance on CF maintenance is time-dependent.
However, use of HTK suggests better protection against
development of tissue edema.
To better evaluate the efficiency of myocardial
protection was made a study of multiple comparisons
between treatments (Table 1). Table 2 shows the chemical
composition of the solutions studied. For HR, only CEL
versus HTK were not significantly different. For LVSP, (+dP/
dt), (-dP/dt) and CF, all comparisons were significantly
different. Overall, use of CEL resulted in significant
improvement in hemodynamic variable outcome compared
to the other solutions.
Table 1. Ratio of hemodynamic variables corresponding (Tukey’s
test - t60).
Dependent Variable
HR
LVSP
+dP/dt
-dP/dt
CF
KHB
HTK
*
CEL
*
*
HTK
KHB
*
CEL
*
*
STH-1
*
*
*
*
*
CEL
*
*
KHB and HTK
*
*
(*) There was statistical difference (p <0.05) between solutions.
There was no statistical difference (P >0.05) only for the solution
quoted. KHB - Krebs-Henseleit Buffer; HTK – Bretschneider-HTK;
STH-1 – St. Thomas-No.1; CEL – Celsior; HR – Heart rate; LVSP
– Left ventricular systolic pressure; (+dP/dt) - Maximum rate of
rise of left ventricular pressure during ventricular contraction; (-
dP/dt) - Maximum rate of fall of left ventricular pressure during
ventricular contraction; CF – Coronary flow
Fig. 5 - Coronary flow (CF) according to the solution. Reperfused
hearts were monitored for 60 min after treatment with the following
solutions: Krebs-Henseleit Buffer, Bretschneider-HTK, St. Thomas
No. 1, and Celsior. Baseline was calculated after stabilization and
prior to treatment
Fig. 4 - Maximum rate of fall in left ventricular pressure (-dP/dt),
according to the solution. Reperfused hearts were monitored for
60 min with the following solutions: Krebs-Henseleit Buffer,
Bretschneider-HTK, St. Thomas No. 1, and Celsior. Baseline was
calculated after stabilization and prior to treatment
Fig. 3 - Maximum rate of rise in left ventricular pressure (+dP/dt),
according to the solution. Reperfused hearts were monitored for
60 min with the following solutions: Krebs-Henseleit Buffer,
Bretschneider-HTK, St. Thomas No. 1, and Celsior. Baseline was
calculated after stabilization and prior to treatment
Fig. 2 - Left ventricle systolic pressure (LVSP) according to the
solution. Reperfused hearts were monitored for 60 min with the
following solutions: Krebs-Henseleit Buffer, Bretschneider-HTK,
St. Thomas No. 1, and Celsior. Baseline was calculated after
stabilization and prior to treatment
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DISCUSSION
Clinical investigations on the comparative performance
of the cardioplegic solutions offer the greatest difficulties
on result interpretation and may bring false judgment.
Langendorff system was chosen because it is well
standardized in our laboratories about myocardial
protection evaluation and is possible also analyzing the
direct effects on the heart with systemic interferences
exclusion [10].
Hypothermia was adopted in this study because it is a
standard strategy of myocardial protection. Cleveland et
al. [11] showed that hypothermia is the most important factor
in myocardial protection. Studies on myocardial protection
with cardioprotective additives, associated with
hypothermia, demonstrated improved contractile function
after long ischemia periods [6].
Pereda et al. [12] compared the performance of Celsior
(CEL) versus St. Thomas No. 2 (STH-2) solutions, as blood
cardioplegia, demonstrating that they were not significantly
different.
Loganathan et al. [13] analyzed the effects of reperfusion
up to 24 hours using Bretschneider-HTK (HTK) solution
and modified Bretschneider-HTK (Custodiol-N). The last
one improves myocardial and endothelial function during
the critical phase of reperfusion after heart transplantation.
Lee et al. [14], contrariwise, found that Bretschneider-
HTK (HTK) solution exhibited superior protective effects
over CEL against prolonged cold ischemia in a syngeneic
rat transplantation model.
The current clinical practice in the Brazilian myocardial
protection in cardiac transplantation commonly uses the
St. Thomas No. 1 (STH-1) crystalloid solution, extracellular
type. Currently, other solutions were added to the
therapeutic arsenal of myocardial protection, such as the
Celsior solution (CEL), extracellular type, and
Bretschneider-HTK solution (HTK), intracellular type (Table
2). Such solutions have been used increasingly in major
transplant centers. Supported in the international literature
we compared the ventricular performance experimentally
using the above solutions in the myocardium of rats
subjected to ischemia and reperfusion.
In the present investigation we adopted the absence of
cardiac pacing to enhance the intrinsic rhythm of the heart.
Additionally, it should be emphasized that the heart’s
conduction tissue is more sensitive to ischemia [15]. Thus,
heart rate is ultimately a variable capable of providing
indirect information on the severity of injury caused by
ischemia and reperfusion [16]. All solutions provided
preservation of the HR, but the results were below the
baseline value for this variable. It was observed that after
30 min of reperfusion, all solutions were stable. Note that
the STH-1 solution took 30 min for stabilization.
The myocardial contractility was assessed in an
integrated manner by the following variables: LVSP, (+dP/
dt), and (-dP/dt). We observed that the effects of ischemia
and reperfusion on the myocardium are extremely
deleterious, producing a marked reduction in ventricular
performance. We infer that the concentrations of K+ (15
mmol/L) and Ca2+ (0.25 mmol/L) of CEL solution can
contribute to a better performance by promoting the
depolarizing arrest without contributing to an overload of
intracellular calcium during the ischemic period [17,18].
Considering that isolated hearts used in this study had
a fixed pressure gradient, essentially the only factor
responsible for decreased blood flow would be related to
interstitial edema. Therefore, by analyzing the behavior of
coronary flow, we aimed to relate it directly to myocardial
edema. The results indicate that HTK solution were those
that produced the highest flow values. The other solutions
used showed a descending order of efficiency in maintaining
coronary flow, as follows: CEL>KHB>STH-1. We suggest
that each solution has an optimal preservation temperature,
where hypothermia can facilitate or interfere with tissue
edema, possibly by directly influencing membrane
conductive properties in myocardial cells, as well as
modifying the permeability of the endothelium [8,19,20].
Moreover, another antagonistic factor to edema
development could be related to the osmotic properties of
each solution used [18,21]. Relative to osmolarity, these
solutions have the following decreasing order: KHB>STH-
Components(mmol/L)
Lactobionate
Manitol
Glutamate
á-Ketoglutarate
Tryptophan
Histidine . HCL.H2O
Histidine
Glutatione
Na+
Glucose
K+
Mg++
Ca2+
NaHCO3
Procaine
pH
Osmolality(mOsm/L)
Table 2. Chemical Composition of the solutions studied
KHB
-
-
-
-
-
-
-
-
126
11.5
4.8
1.2
2.5
2 5
-
7.4 ± 0.5
330
HTK
-
3 0
-
1
2
1 8
180
-
1 5
-
9
4
0.015
-
-
7.4-7.45
310
STH-1
-
-
-
-
-
-
-
-
144
-
2 0
1 6
2.2
1 0
1
7.4
324
CEL
8 0
6 0
2 0
-
-
-
3 0
3
100
-
1 5
1 3
0.25
-
-
7.4 ± 0.2
320
KHB - Krebs-Henseleit Buffer; HTK – Bretschneider-HTK; STH-
1 – St. Thomas-No.1; CEL – Celsior
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1>CEL>HTK. However, we did not observe this same order
considering comparative performance. Additionally, Na+ is
also an important variable in this process, and these
solutions have the following decreasing order in
concentration of this ion: STH-1>KHB>CEL>HTK. The
comparative performances between them do not obey this
order, indicating that Na+ is not solely responsible for the
participation of edema [21].
This study is part of a line of research that includes
endothelial dysfunction and apoptosis using different
cardioprotective methods, and has inherent limitations.
Perfusion of non-human isolated hearts with solutions
without blood produces disturbances in cardiac
performance. However, even though the data obtained
cannot be translated directly to clinical application, one
must consider that comparative studies with animal models
have proven effective in research related to myocardial
preservation [22,23].
CONCLUSION
Despite the cardioprotective crystalloid solutions
studied are not fully able to suppress the deleterious effects
of ischemia and reperfusion in the rat heart, the CEL solution
had significantly higher results followed by
HTK>KHB>STH-1. Other researches are still needed,
considering different infusion temperatures and others
cardioplegic solutions to extend the cardioprotective
methods.
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